Figure 1

The statistical analyses of databases. (A) A comparison of TP53 wild type allele retention occurrence in human cancer cell lines with samples from surgeries and biopsies (marked as tumour samples) showing mutation, Χ² test was performed for cell lines vs tumour samples. (B) A comparison of ROH/LOH 17p occurrence in human cancer cell line showing mutation and tumour samples, Χ² test was performed. (C) A comparison of incidence of 1/more than 1 TP53 mutation in human cancer cell lines and tumour samples, Χ² test was performed. (D) A comparison of TP53 wild type allele retention occurrence in human cancer cell lines and tumour samples with the distinction between missense and nonsense mutation (sample was categorized as "missense" in case of at least 1 missense mutation, while "nonsense" with no missense mutations), Χ² test was performed for cell-lines and tumour samples separately. (E) A comparison of incidence of at least one TP53 mutation outside exons 5-8 versus all TP53 mutations within exons 5-8 in human cancer cell lines and tumour samples showing 2 or more TP53 mutations, Χ² test was performed. (F) A comparison of TP53 wild type allele retention occurrence in human cancer cell lines and tumour samples with mutations characteristic for dominant-negative effect (codons 175, 248, 273, with distinction for R273C, as with no DNE, and other types of mutation of codon 273 - marked R273X), Χ² test was performed for each analysis.